Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 75, Issue -, Pages 112-128Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2014.05.018
Keywords
siRNA; Pulmonary delivery; Nanocarrier; Polymer; Lung cancer; Asthma
Categories
Funding
- Wayne State Start-Up Fund
- BOOST Award
- FRAP Award
- NIH [1U01NS083457]
- DVA grant [1I01BX001514]
Ask authors/readers for more resources
RNA interference (RNAi) has been thought of as the general answer to many unmet medical needs. After the first success stories, it soon became obvious that short interfering RNA (siRNA) is not suitable for systemic administration due to its poor pharmacokinetics. Therefore local administration routes have been adopted for more successful in vivo RNAi. This paper reviews nucleic acid modifications, nanocarrier chemistry, animal models used in successful pulmonary siRNA delivery, as well as clinical translation approaches. We summarize what has been published recently and conclude with the potential problems that may still hamper the efficient clinical application of RNAi in the lung. (C) 2014 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available